ALLI

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Lithuania, Netherlands, Poland, Singapore, South Africa, Spain, UK.

Active ingredients

The drug ALLI contains one active pharmaceutical ingredient (API):

1	Orlistat UNII 95M8R751W8 - ORLISTAT
	Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides.
	Read more about Orlistat

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A08AB01	Orlistat	A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AB Peripherally acting antiobesity products
Discover more medicines within A08AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1395301, 1395356, 1395367, 1395378, 1489709, 1506473, 1506484, 1506495, 1506507, 1538715
ES	Centro de información online de medicamentos de la AEMPS	07401009, 07401011
GB	Medicines & Healthcare Products Regulatory Agency	156156, 180484
LT	Valstybinė vaistų kontrolės tarnyba	1036158, 1036159, 1036160, 1036161, 1056312, 1057897, 1057898, 1057899, 1057900, 1063632
NL	Z-Index G-Standaard, PRK	89117
PL	Rejestru Produktów Leczniczych	100201563, 100239399
SG	Health Sciences Authority	13782P
ZA	Health Products Regulatory Authority	43/11.3/0192